| 2.98 -0.11 (-3.56%) | 06-10 11:30 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.97 | 1-year : | 4.7 |
| Resists | First : | 3.4 | Second : | 4.02 |
| Pivot price | 3.07  |
|||
| Supports | First : | 2.39 | Second : | 1.99 |
| MAs | MA(5) : | 3.27  |
MA(20) : | 2.98 |
| MA(100) : | 4.4 |
MA(250) : | 5.29 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 41.9 |
D(3) : | 50.6 |
| RSI | RSI(14): 47 |
|||
| 52-week | High : | 8.77 | Low : | 2.39 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ QTRX ] has closed above bottom band by 47.2%. Bollinger Bands are 9.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.26 - 3.28 | 3.28 - 3.3 |
| Low: | 2.86 - 2.89 | 2.89 - 2.9 |
| Close: | 3.06 - 3.09 | 3.09 - 3.12 |
Quanterix Corporation, based in Billerica, Massachusetts, is a life sciences enterprise dedicated to pioneering and commercializing advanced digital immunoassay platforms. These sophisticated systems are designed to enhance precision health in both scientific research and diagnostic applications, reaching markets across North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company's core offerings include several innovative instruments: The HD-X instrument, which provides highly sensitive and automated multiplex protein detection. The SR-X instrument, enabling researchers to leverage Simoa detection technology for diverse uses, such as the direct detection of nucleic acids. The SP-X instrument, which utilizes Simoa planar array technology for conducting multiplex chemiluminescent immunoassays. Alongside these platforms, Quanterix also supplies crucial consumables, including assay kits and reagents. In addition to its product line, the company delivers various contract research services, encompassing sample analysis, the development of custom "homebrew" assays, and other specialized research and development projects. Quanterix's operational focus spans critical health areas like neurology, oncology, cardiology, infectious diseases, and inflammation. Its clientele within the life science research sector primarily consists of laboratories affiliated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research organizations. Sales are managed through a multifaceted approach, combining a direct sales force, dedicated support organizations, and a network of distributors or sales agents. The company was initially incorporated in 2007 as Digital Genomics, Inc., before rebranding to Quanterix Corporation in August of the same year.
Wed, 10 Jun 2026
Quanterix names Jason Faessler as CFO - MSN
Tue, 09 Jun 2026
Transcript : Quanterix Corporation Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 01 - marketscreener.com
Tue, 09 Jun 2026
QTRX: Diagnostics expansion, innovation, and partnerships set the stage for growth and margin improvement - TradingView
Tue, 09 Jun 2026
Quanterix stock falls on CFO appointment announcement - Investing.com
Tue, 09 Jun 2026
Quanterix appoints Jason Faessler as CFO and Treasurer - TradingView
Tue, 09 Jun 2026
Jason Faessler joins Quanterix (QTRX) as Chief Financial Officer and Treasurer - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 47 (M) |
| Shares Float | 38 (M) |
| Held by Insiders | 6.2 (%) |
| Held by Institutions | 85.4 (%) |
| Shares Short | 5,150 (K) |
| Shares Short P.Month | 4,300 (K) |
| EPS | -2.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.98 |
| Profit Margin | -71.9 % |
| Operating Margin | -59.2 % |
| Return on Assets (ttm) | -13.4 % |
| Return on Equity (ttm) | -34.9 % |
| Qtrly Rev. Growth | 20.1 % |
| Gross Profit (p.s.) | 1.39 |
| Sales Per Share | 3.07 |
| EBITDA (p.s.) | -1.36 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -81 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | -1.3 |
| PEG Ratio | 0 |
| Price to Book value | 0.5 |
| Price to Sales | 0.98 |
| Price to Cash Flow | -1.76 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|